Singular Genomics in pact with TwinStrand Biosciences for next gen sequencing

Jun. 06, 2022 4:35 PM ETSingular Genomics Systems, Inc. (OMIC)QGEN, ABy: Dulan Lokuwithana, SA News Editor

Solution Concept with Handshake on Chalkboard Background

phototechno/iStock via Getty Images

  • Life sciences company, Singular Genomics Systems (NASDAQ:OMIC) has partnered with Seattle-based startup TwinStrand Biosciences, Inc. to develop next-generation sequencing (NGS) solutions for Singular‘s G4 sequencing platform, the companies announced on Monday.
  • Per the terms, Singular and TwinStrand will leverage their respective technologies in Q50+ High Definition Sequencing and TwinStrand Duplex Sequencing to co-develop highly sensitive applications for minimal residual disease (MRD) detection.
  • An indicator of the future outcome of cancer, MRD is important in a wide range of uses such as treatment planning and drug development.
  • The partnership will broaden the product portfolio of both companies, Singular (OMIC) and TwinStrand said.
  • Early this year, La Jolla, California-based Singular (OMIC) announced partnerships with Agilent (A) and COVID-19 test maker QIAGEN for the G4 sequencing platform.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.